Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1524-1530

  Hewitt, Stephen M ^a   Badve, Sunil S ^b   True, Lawrence D ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA FRAGMENT; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN; RNA;

ANALYTIC METHOD; ASSAY; BLOOD SAMPLING; BODY FLUID; CLINICAL PROTOCOL; DNA SEQUENCE; FORENSIC IDENTIFICATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL HISTORY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VALIDITY;

BODY FLUIDS; DNA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEINS; RESEARCH DESIGN; RNA; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84858227016     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2204     Document Type: Review

References (29)

1. Gal AA. In search of the origins of modern surgical pathology. Adv Anat Pathol 2001;8:1-13.
2. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008;132:1929-35.
3. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-76.
4. Owzar K, Barry WT, Jung SH, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res 2008;14:5959-66.
5. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012;18:1515-23.
6. Schilsky RL, Doroshow JH, LeBlanc M, Conley BA. Development and use of integral assays in clinical trials. Clin Cancer Res 2012;18:1540-6.
7. Hewitt SM, Takikita M, Braunschweig T, Chung J-Y. Promises and challenges of predictive tissue biomarkers. Biomark Med 2007;1:313-8.
8. Clinical and Laboratory Standards Institute. Quality assurance for design control and implementation of immunohistochemical assays: approved guidelines. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
9. Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM. Lessons learned from the Investigational Device Exemption review of Children's Oncology Group Trial AAML1031. Clin Cancer Res 2012;18:1547-54.
10. Chung JY, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, et al. Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 2008;56:1033-42.
11. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 2006;3:409-26. (Pubitemid 44231984)
12. Barelli S, Crettaz D, Thadikkaran L, Rubin O, Tissot JD. Plasma/serum proteomics: pre-analytical issues. Expert Rev Proteomics 2007;4:363-70. (Pubitemid 46890073)
13. Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, et al. Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteomics 2010;73:579-92.
14. Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, et al. Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 2008;26:5638-44.
15. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42. (Pubitemid 38364587)
16. Xie R, Chung JY, Ylaya K, Williams RL, Guerrero N, Nakatsuka N, et al. Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. J Histochem Cytochem 2011;59:356-65.
17. Yi J, Liu Z, Craft D, O'Mullan P, Ju G, Gelfand CA. Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. J Proteome Res 2008;7:5112-8.
18. National Cancer Institute [homepage on the Internet]. NCI best practices for biospecimen resources [cited 2012 Feb 23]. Available from: http://biospecimens.cancer.gov/bestpractices/
19. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-55.
20. Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology - National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19, 2005. Clin Chem 2006;52:1669-74. (Pubitemid 44330699)
21. Court M, Selevsek N, Matondo M, Allory Y, Garin J, Masselon CD, et al. Toward a standardized urine proteome analysis methodology. Proteomics 2011;11:1160-71.
22. Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, Carvalho B, et al. Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays. Genes Chromosomes Cancer 2008;47:957-64.
23. Koboldt DC, Ding L, Mardis ER, Wilson RK. Challenges of sequencing human genomes. Brief Bioinform 2010;11:484-98.
24. Nothnagel M, Herrmann A, Wolf A, Schreiber S, Platzer M, Siebert R, et al. Technology-specific error signatures in the 1000 Genomes Project data. Hum Genet 2011;130:505-16.
25. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
26. Klopfleisch R, Weiss AT, Gruber AD. Excavation of a buried treasure - DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol 2011;26:797-810.
27. Coons AH, Creech HJ, Jone RN, et al. The demonstration of pneumococcal antigen in tissues by the use of fluorescent antibodies. J Immunol 1942;45:159-70.
28. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
29. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG; Members of Ad-Hoc Committee on Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 2007;15:124-33. (Pubitemid 46828218)